Blauvelt, A., Reich, K., Mehlis, S., Vanaclocha, F., Sofen, H., Abramovits, W., . . . Tyring, S. (2017). Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study. J Eur Acad Dermatol Venereol.
Citação norma ChicagoBlauvelt, A., et al. "Secukinumab Demonstrates Greater Sustained Improvements in Daily Activities and Personal Relationships Than Ustekinumab in Patients With Moderate‐to‐severe Plaque Psoriasis: 52‐week Results From the CLEAR Study." J Eur Acad Dermatol Venereol 2017.
MLA CitationBlauvelt, A., et al. "Secukinumab Demonstrates Greater Sustained Improvements in Daily Activities and Personal Relationships Than Ustekinumab in Patients With Moderate‐to‐severe Plaque Psoriasis: 52‐week Results From the CLEAR Study." J Eur Acad Dermatol Venereol 2017.